FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226079648> ?p ?o ?g. }

• W4226079648 endingPage "176" @default.
• W4226079648 startingPage "165" @default.
• W4226079648 abstract "No studies evaluating the rapidity of response to biological therapies are available for Crohn's disease (CD). The aim of this study was to evaluate rapidity of onset of clinical response and impact on quality of life (QoL) of adalimumab therapy in adult anti-TNF-naïve patients with moderately-to-severely active CD. RAPIDA was an open-label, single-arm, prospective, multicenter clinical trial. Adult patients with moderately-to-severely active luminal CD, anti-TNF-naïve, and unresponsive to conventional therapy were treated with adalimumab. Clinical disease activity, QoL and inflammatory biomarkers were measured at day 4, and weeks 1, 2, 4, and 12 after treatment initiation. Eighty-six patients were included in the intention-to-treat (ITT) analyses. Clinical disease activity was reduced from a median of 9.0 points to 6.0 points at day 4. Clinical response (≥ 3-point reduction in the Harvey-Bradshaw Index, HBI) was achieved by 61.6% (d4) and 75.6% (w1) of patients in the ITT population (median 2.5 days) and with non-responder imputation (NRI), by 55.8% and 53.4%, respectively. The proportion of patients in clinical remission (HBI < 5) at weeks 2 and 4 in the ITT population was 54.7% and 62.8%, respectively (median 7.0 days), and 38.4% and 45.3% in the NRI population. All QoL scores significantly improved and inflammatory biomarkers significantly decreased from day 4 onwards (p < 0.0001). Rapid clinical response and remission, improvement in QoL and fatigue, and a reduction of inflammatory biomarkers were achieved with adalimumab as early as day 4 in adult anti-TNF-naïve patients with moderately-to-severely active CD. No hay estudios que evalúen la rapidez de la respuesta a las terapias biológicas en la enfermedad de Crohn (EC). El objetivo fue evaluar la rapidez del inicio de la respuesta clínica y el impacto en la calidad de vida (CdV) de la terapia con adalimumab en pacientes adultos con EC moderada-grave. RAPIDA fue un ensayo clínico abierto, de un solo brazo, prospectivo y multicéntrico. Se trató con adalimumab a pacientes adultos con EC luminal activa moderada-grave, sin tratamiento previo con anti-TNF y sin respuesta a terapia convencional. Se midieron la actividad clínica de la enfermedad, la CdV y los biomarcadores inflamatorios el día 4 y las semanas 1, 2, 4 y 12 tras el tratamiento. Se incluyeron 86 pacientes en los análisis por intención de tratar (IdT). La actividad clínica de la enfermedad se redujo de una mediana de 9,0 a 6,0 puntos en el día 4. La respuesta clínica (reducción ≥3 puntos en el Índice Harvey-Bradshaw, IHB) se dio en un 61,4% (d4) y un 75,6% (s1) de los pacientes IdT y en un 55,8% y un 53,4% con imputación de no respondedores (INR). La proporción de pacientes IdT en remisión clínica (IHB<5) en las s2 y s4 fue de 54,7% y 62,8%, respectivamente, y 38,4% y 45,3% en la población INR. Todas las puntuaciones de CdV mejoraron significativamente y los biomarcadores inflamatorios disminuyeron significativamente desde el día 4 (p<0,0001). Se logró una rápida respuesta clínica y remisión, mejoría en la CdV y fatiga, y una reducción de los biomarcadores inflamatorios en los pacientes tratados con adalimumab ya en el día 4." @default.
• W4226079648 created "2022-05-05" @default.
• W4226079648 creator A5007019089 @default.
• W4226079648 creator A5009378311 @default.
• W4226079648 creator A5011593256 @default.
• W4226079648 creator A5023730578 @default.
• W4226079648 creator A5028145761 @default.
• W4226079648 creator A5031317742 @default.
• W4226079648 creator A5033282443 @default.
• W4226079648 creator A5040944358 @default.
• W4226079648 creator A5043396998 @default.
• W4226079648 creator A5046714802 @default.
• W4226079648 creator A5046814332 @default.
• W4226079648 creator A5049138418 @default.
• W4226079648 creator A5051728887 @default.
• W4226079648 creator A5052947148 @default.
• W4226079648 creator A5053104917 @default.
• W4226079648 creator A5056652716 @default.
• W4226079648 creator A5085311341 @default.
• W4226079648 creator A5091186900 @default.
• W4226079648 date "2022-03-01" @default.
• W4226079648 modified "2023-10-17" @default.
• W4226079648 title "Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study" @default.
• W4226079648 cites W1562131205 @default.
• W4226079648 cites W1886704136 @default.
• W4226079648 cites W1968616184 @default.
• W4226079648 cites W1985746774 @default.
• W4226079648 cites W1991810959 @default.
• W4226079648 cites W2006360844 @default.
• W4226079648 cites W2008497900 @default.
• W4226079648 cites W2022661087 @default.
• W4226079648 cites W2024959214 @default.
• W4226079648 cites W2041428141 @default.
• W4226079648 cites W2055211617 @default.
• W4226079648 cites W2065235857 @default.
• W4226079648 cites W2089176308 @default.
• W4226079648 cites W2111570058 @default.
• W4226079648 cites W2125626931 @default.
• W4226079648 cites W2125799301 @default.
• W4226079648 cites W2129558176 @default.
• W4226079648 cites W2149170290 @default.
• W4226079648 cites W2152026434 @default.
• W4226079648 cites W2163123800 @default.
• W4226079648 cites W2170393161 @default.
• W4226079648 cites W2171341132 @default.
• W4226079648 cites W2521454913 @default.
• W4226079648 cites W2523706394 @default.
• W4226079648 cites W2563342462 @default.
• W4226079648 cites W2757742334 @default.
• W4226079648 cites W4231630787 @default.
• W4226079648 cites W4237097915 @default.
• W4226079648 doi "https://doi.org/10.1016/j.gastre.2021.04.007" @default.
• W4226079648 hasPublicationYear "2022" @default.
• W4226079648 type Work @default.
• W4226079648 citedByCount "0" @default.
• W4226079648 crossrefType "journal-article" @default.
• W4226079648 hasAuthorship W4226079648A5007019089 @default.
• W4226079648 hasAuthorship W4226079648A5009378311 @default.
• W4226079648 hasAuthorship W4226079648A5011593256 @default.
• W4226079648 hasAuthorship W4226079648A5023730578 @default.
• W4226079648 hasAuthorship W4226079648A5028145761 @default.
• W4226079648 hasAuthorship W4226079648A5031317742 @default.
• W4226079648 hasAuthorship W4226079648A5033282443 @default.
• W4226079648 hasAuthorship W4226079648A5040944358 @default.
• W4226079648 hasAuthorship W4226079648A5043396998 @default.
• W4226079648 hasAuthorship W4226079648A5046714802 @default.
• W4226079648 hasAuthorship W4226079648A5046814332 @default.
• W4226079648 hasAuthorship W4226079648A5049138418 @default.
• W4226079648 hasAuthorship W4226079648A5051728887 @default.
• W4226079648 hasAuthorship W4226079648A5052947148 @default.
• W4226079648 hasAuthorship W4226079648A5053104917 @default.
• W4226079648 hasAuthorship W4226079648A5056652716 @default.
• W4226079648 hasAuthorship W4226079648A5085311341 @default.
• W4226079648 hasAuthorship W4226079648A5091186900 @default.
• W4226079648 hasConcept C126322002 @default.
• W4226079648 hasConcept C141071460 @default.
• W4226079648 hasConcept C159110408 @default.
• W4226079648 hasConcept C2779134260 @default.
• W4226079648 hasConcept C2779280984 @default.
• W4226079648 hasConcept C2779951463 @default.
• W4226079648 hasConcept C2780132546 @default.
• W4226079648 hasConcept C2908647359 @default.
• W4226079648 hasConcept C535046627 @default.
• W4226079648 hasConcept C71924100 @default.
• W4226079648 hasConcept C90924648 @default.
• W4226079648 hasConcept C99454951 @default.
• W4226079648 hasConceptScore W4226079648C126322002 @default.
• W4226079648 hasConceptScore W4226079648C141071460 @default.
• W4226079648 hasConceptScore W4226079648C159110408 @default.
• W4226079648 hasConceptScore W4226079648C2779134260 @default.
• W4226079648 hasConceptScore W4226079648C2779280984 @default.
• W4226079648 hasConceptScore W4226079648C2779951463 @default.
• W4226079648 hasConceptScore W4226079648C2780132546 @default.
• W4226079648 hasConceptScore W4226079648C2908647359 @default.
• W4226079648 hasConceptScore W4226079648C535046627 @default.
• W4226079648 hasConceptScore W4226079648C71924100 @default.
• W4226079648 hasConceptScore W4226079648C90924648 @default.
• W4226079648 hasConceptScore W4226079648C99454951 @default.

• next